The controversy began when reports surfaced suggesting that Pfizer had aggressively marketed its COVID-19 vaccine without providing comprehensive safety data.Critics argue that the company promoted the vaccine for widespread use while not fully disclosing all of the clinical data related to its safety and efficacy, particularly in the early stages of the vaccine rollout. This raised questions about whether Pfizer had acted prematurely in its promotional efforts and if the public had received all the necessary information to make informed decisions about the vaccine.